<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2679846</article-id><article-id pub-id-type="pmc">2247328</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>K&#x000c3;&#x000b6;ppler</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pfl&#x000c3;&#x000bc;ger</surname><given-names>K. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Eschenbach</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pfab</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lennert</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wellens</surname><given-names>W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gassel</surname><given-names>W. D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kolb</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>H&#x000c3;&#x000a4;ssler</surname><given-names>R.</given-names></name></contrib><etal/></contrib-group><aff>Department of Internal Medicine, Philipps-University, Marburg, Federal Republic of Germany.</aff><pub-date pub-type="ppub"><month>7</month><year>1989</year></pub-date><volume>60</volume><issue>1</issue><fpage>79</fpage><lpage>82</lpage><abstract><p>Sixty previously untreated patients with high grade non-Hodgkin's lymphomas stages II-IV received cyclophosphamide 750 mg m2 i.v., doxorubicin 50 mg m2 i.v., and vincristine 2 mg i.v. on day 1, prednisolone 100 mg p.o. on days 1-5 and etoposide 100 mg m2 i.v. on days 3-5 (CHOP-VP16). After four courses an involved field irradiation with a total dose of 25 Gy was employed and followed by two additional courses of CHOP-VP16. The overall response rate was 93%, with 49 patients (82%) achieving a complete remission (CR). Seven patients had a partial response and four patients showed no response. During a median follow-up period of 55 months, 22 of the 49 patients with CR relapsed, seven of them achieving a second complete remission with the same drug regimen. A maintained complete remission of up to 68 months was seen in 55% of all patients initially achieving CR. The median survival is 43 months. Mean side-effects of this drug regimen were alopecia (89%), nausea/vomiting (76%) and leukopenia (61%). No therapy-related deaths were seen. The results of this study demonstrate that this combined modality treatment produces high complete remission rates and that more than half of these patients achieve long-term disease-free survival.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00117-0089.tif" xlink:title="scanned-page" xlink:role="79" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00117-0090.tif" xlink:title="scanned-page" xlink:role="80" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00117-0091.tif" xlink:title="scanned-page" xlink:role="81" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00117-0092.tif" xlink:title="scanned-page" xlink:role="82" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

